Skip to main content
. 2021 Jul;10(7):3106–3119. doi: 10.21037/tlcr-21-52

Figure 5.

Figure 5

Forest plots for safety endpoints indirect comparisons among combination regimens (IO, IO + CT, Combo IO) according to different IO agents: anti-PD-1 (A); anti-PD-L1 (B). IO, single-agent immunotherapy; IO + CT, immunotherapy plus standard platinum-based doublet; Combo IO, immunotherapy combination regimens; TRAEs, treatment-related adverse events.